Low MLKL expression has been associated with poor prognosis in patients with breast, ovarian, gastric, colon, and pancreatic cancers.68 In animal studies, intratumoral delivery of an autoactive RIPK3 construct or the use of necroptotic cells as a vaccination strategy generated efficient antitumoral immune responses.69,70 Interestingly, effective antitumor immunity depends on the NFκB pathway rather than on MLKL-dependent disruption of cell integrity. The gene discussed is MLKL; the disease is familial pancreatic carcinoma.